Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
「虎に翼」直言の最期にネット反響「ぽかん」「あげくのナレ死」「お父さん…チャーミングすぎ」
太田光、今くるよさんしのぶ「いくよ師匠が亡くなってから寂しそうだった、痩せちゃって」
太田光「小池百合子と蓮舫って究極の選択」都知事選に私見「俺、選べねーな、どっちも大好き」
ドジャース9回土壇場でスクイズ、同点に追いつき延長戦へ、大谷翔平は4打席まで無安打
「虎に翼」効果に沸くロケ地 「ここまでとは」担当者も驚きの声
ドジャースが執念のスクイズで同点からの打線お目覚め 大谷翔平は5の0も連敗は5でストップ
ハイヒール・モモコ、今くるよさん死去に「大好きないくよ姉さんと漫才して」
UL Solutionsがバッテリーエンクロージャ材料スクリーニング試験所を日本に開所、EV用バッテリーの安全性向上に貢献
ジョージアで「ロシア法」成立へ 反体制派の弾圧懸念 欧米は反発
渡辺直美、36歳で知った衝撃日本語を告白 あることわざを勘違いで「ぼうぼう」言ってた…
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
小倉優子、不自然な“二重ライン”にネット騒然「やっぱり整形?」
大原櫻子、ガーシー暴露後初のSNS投稿に賛否の声「イメージ最悪になった」
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
漫才師の今くるよさん死去 膵がんのため
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
トミーズ健、父が遺した口座解約で銀行とトラブルも…「真実」にガックリ
藤田ニコル「初めてした日」ゆうちゃみ「体位とかも全部」親に明かしたギャル的「性事情」に騒然
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
元めちゃイケメンバーの三中元克(32)現在は何をしているのか調べてみた!
ヒカル、浮気相手とのLINE流出にドン引きの声「キモすぎる」「吐きそう」
ガーシーが綾野剛のLINE公開でネット騒然「ショック」「すごいエンタメ」
TikTokを賑わす「フエラムネごめんなサイダー味」がセブンイレブンで再販!じゅるるマスカットも買うなら今!
小倉優子、不自然な“二重ライン”にネット騒然「やっぱり整形?」
完全にダマされた! 『ラヴィット!』あのちゃん“事故レベル”大暴走は『水ダウ』遠隔操作のしわざだった ネットも納得
「虎に翼」直言の最期にネット反響「ぽかん」「あげくのナレ死」「お父さん…チャーミングすぎ」
太田光、今くるよさんしのぶ「いくよ師匠が亡くなってから寂しそうだった、痩せちゃって」
太田光「小池百合子と蓮舫って究極の選択」都知事選に私見「俺、選べねーな、どっちも大好き」
ドジャース9回土壇場でスクイズ、同点に追いつき延長戦へ、大谷翔平は4打席まで無安打
「虎に翼」効果に沸くロケ地 「ここまでとは」担当者も驚きの声
ドジャースが執念のスクイズで同点からの打線お目覚め 大谷翔平は5の0も連敗は5でストップ
ハイヒール・モモコ、今くるよさん死去に「大好きないくよ姉さんと漫才して」
UL Solutionsがバッテリーエンクロージャ材料スクリーニング試験所を日本に開所、EV用バッテリーの安全性向上に貢献
ジョージアで「ロシア法」成立へ 反体制派の弾圧懸念 欧米は反発
渡辺直美、36歳で知った衝撃日本語を告白 あることわざを勘違いで「ぼうぼう」言ってた…